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Drusen are a feature of age-related macular degeneration
(AMD). Lesions similar in appearance to drusen are also
found in the fundi of patients with membranoproliferative
glomerulonephritis type II (dense deposit disease, DDD). The
lamina densa of the glomerular basement membrane, in
DDD, is transformed into an electron-dense structure by
deposition of microscopically homogeneous material. Our
study sought to compare the saccharide composition of
drusen and dense deposits in the formalin-fixed, paraffin-
embedded tissue from the eye and kidney. Six eye specimens
were obtained from patients diagnosed with AMD but
another eye was obtained from a patient with partial
lipodystrophy, who died after renal failure presumably
because of DDD. The kidney specimens were from three
biopsy-proven cases of DDD. Glycosylation patterns were
measured by the binding of 19 biotinylated lectins before
and after neuraminidase pre-treatment. High mannose, bi/tri-
antennary non-bisected and bisected complex N-glycan,
N-acetyl glucosamine, galactose, and sialic acid residues were
found in both drusen and dense deposits. Treatment with
neuraminidase exposed subterminal galactose in both sites
and sparse N-acetyl galactosamine residues in drusen alone.
Our study found similar pathologic oligosaccharide structures
in the eye and kidney, suggesting that drusen may be a
common end result of retinal and glomerular disease.
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Mesangiocapillary, or membranoproliferative, glomerulone-
phritis type II is a rare disease affecting only 2–3 people per
million population.1 It is characterized by the appearance of a
ribbon-like structure of diffuse electron dense material within
the glomerular basement membrane (GBM), accompanied
occasionally by subendothelial and subepithelial deposits.2–4
These intramembranous deposits, found within the substance
of the GBM, are the pathognomonic feature of this type of
glomerulonephritis, and the descriptive label dense deposit
disease (DDD) is now the preferred term for the condition.
Patients may present with a nephrotic syndrome (hypoalbu-
minemia, proteinuria, and edema), or with hematuria and/or
proteinuria in the non-nephrotic range. They progress
frequently to end-stage renal failure. These patients may
also, typically, have partial lipodystrophy5 and frequently, if
not invariably, develop drusen-like deposits very similar to
those seen in age-related macular degeneration (AMD) but at
a much earlier age.3,6–9 Over 80% of patients with DDD have
C3 nephritic factor , an auto-antibody against C3 convertase
of the alternate pathway, resulting in the loss of alternate
pathway control; C3 nephritic factor acts to stabilize C3
convertase and so increases C3 catabolism which results in a
lowered serum level. Alternatively, patients may have a
mutation in complement factor H or complement factor
H-related protein 5 genes which also results in dysregulation
of the alternate pathway.1,3,4,10,11 Drusen in AMD are also
believed to be due to an inflammatory response and
activation of the alternate pathway.12 This study aims to
compare the oligosaccharide distribution in the dense
deposits of the kidney with the drusen-like lesions in the
eyes of a patient with presumed DDD (patient A), and
drusen from patients with AMD using lectin histochemistry.
RESULTS
Drusen in AMD and patient A, and glomerular dense
deposits, showed similar lectin-binding patterns. Eight lectin
probes––Con-A, PSA, LCA, e-PHA (Figure 1a and b), MPA,
DSA (Figure 1c and d), WGA, and SNA––bound to drusen
and dense deposits (Table 1). AHA, BSA-1B4, CTA, DBA,
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ECA (Figure 2a, c and e), LTA, MAA, l-PHA, SBA, and
UEA-1 did not bind to either drusen or dense deposits. CTA,
ECA (Figure 2b, d and f), MPA, PSA, and Jac showed binding
or increased binding to both drusen and dense deposits after
neuraminidase pre-treatment (Table 2). AHA and SBA
bound to drusen but not dense deposits after neuraminidase
pre-treatment. SNA showed decreased binding after neur-
aminidase pre-treatment to both dense deposits and drusen,
whereas binding with MAA was not altered.
No binding was observed when the lectin was replaced
with buffer alone, and incubation of the lectin with its
competing sugar produced abolition or reduction of stain.
The GBM and the tubular basement membrane of the
normal kidney bound to MPA after neuraminidase pre-
treatment.
As UEA-1, DBA, and BSA-1B4 did not bind to the drusen
or other ocular structures, we do not consider the effect of
blood group antigen as significant in the interpretation of our
results.
DISCUSSION
This study shows clearly that the oligosaccharide composi-
tion of drusen in AMD and DDD, and the glomerular dense
deposits in DDD are similar, as shown by the lectin-binding
patterns. Lectins are glycoproteins which can bind reversibly
to specific saccharide sequences by at least two binding
sites.13 As the specificities of the lectins are known, the
saccharides present can be identified.14
In this study, both AHA and SBA exhibited increased
binding to drusen but no binding to the dense deposits in the
kidney after neuraminidase pre-treatment, indicating the
presence of subterminal galactose (AHA) and N-acetyl
galactosamine (SBA) in drusen but not in dense deposits.
One could postulate that proteins linked to galactose and
GalNAc residues were not detected in dense deposits, because
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Figure 1 | Comparison between lectin binding of drusen and
renal dense deposits. (a) e-PHA-bound drusen in DDD with
moderate to strong intensity (þ 3). (b) e-PHA-bound renal dense
deposits with moderate to strong intensity (þ 3), (c) DSA-bound
drusen in age-related macular degeneration (AMD) with moderate
to strong intensity (þ 3). (d) DSA-bound renal dense deposits
with moderate to strong intensity (þ 3). Black arrow indicates
drusen and yellow arrows indicate dense deposits.
Table 1 | Comparison of intensity of lectin binding between
drusen and dense deposits of the kidney
Specimen CON-A PSA LCA e-PHA Jac MPA WGA DSA SNA
AMD drusen 2 3 2 2 1 2 2 3 3
DDD drusen 2 2 2 2 0 2 3 3 4
Dense deposits 2.5 1.5 1 1 0 2 2.5 3 2
Key: 0=no binding, 1=weak, 2=moderate, 3=moderately strong, and 4=intense
l-PHA, AHA, ECA, CTA, BSA-1B4, SBA, DBA, LTA, UEA-1, and MAA did not bind.
Table 2 | Effect of neuraminidase on intensity of lectin
binding of drusen and dense deposits
Specimen PSA SBA AHA Jac MPA ECA CTA WGA SNA MAA
AMD drusen (3) m(1) m(2) m(3) (2) m(3) m(2) (2) k(1) (0)
DDD drusen m(3) m(1) m(2) m(1) (2) m(3) m(2) (3) k(2) (0)
Dense deposits m(2) (0) (0) m(2) (2) m(3) m(2) (2.5) k(0) (0)
Key: 0=no binding, 1=weak, 2=moderate, 3=moderately strong, and 4=intense
binding; m indicate increase, k decrease, and  indicates no change.
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Figure 2 | Effect of neuraminidase on binding of ECA. (a) No
binding to drusen in DDD glomerulonephritis prior to pre-
treatment with neuramindase. (b) Binding detected after pre-
treatment with neuraminidase. (c) No binding to drusen in age-
related macular degeneration (AMD) prior to pre-treatment with
neuraminidase. (d) Binding detected after pre-treatment with
neuraminidase. (e). No binding to renal dense deposits in DDD
prior to pre-treatment with neuraminidase. (f) Binding detected
after pre-treatment with neuraminidase. Black arrows indicate
drusen and yellow arrows indicate dense deposits.
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access to them may be prevented by the polyanionic nature of
the lamina rara externa.
Apart from these specific lectins described above, there
were remarkable similarities in the lectin-binding pattern of
drusen and the dense deposits in the kidney. High mannose
and small complex sequences (Con-A), complex bisected
(ePHA), and non-bisected (PSA) bi/tri-antennate complex
N-glycan were present in both, whereas tetra-antennate
complex N-glycan (l-PHA) was found in neither. Sialic acid
in a2,6-linkage was evident in both sites (SNA), although not
a2,3-linked, as shown by the absence of binding with MAA.
Repeating GlcNAc sequences (DSA, WGA) and subterminal
galactose, bound by CTA, were present in both drusen and
dense deposits, whereas fucose (LTA, UEA-1) was present in
neither.
Nevins15 did not detect binding of the dense deposits with
Con-A which was a feature of this study. Curiously though,
he detected complement component C3, which is a
glycoprotein containing high mannose16 to which Con-A
binds. Nevins did not detect binding of dense deposits with
AHA and SBA even after pre-treatment with neuraminidase.
Both AMD and DDD may be associated with a functional
defect in complement factor H,17 which is an important
regulator of the alternate pathway of the complement system.
DDD is also associated with the presence of C3 nephritic
factor, an antibody against C3 convertase of the alternate
pathway that prolongs the half-life of C3 10-fold.18 Proteins
that regulate the complement cascade, such as vitronectin,
clusterin,9 and apolipoprotein E19 have been shown in
drusen, suggesting the importance of complement activation
in the biogenesis of drusen associated with AMD. Activation
of complement, the presence of which can be correlated with
the lectin-binding pattern we observed, can initiate cell lysis
and disruption of Bruch’s membrane and retinal pigment
epithelium integrity. The blood retinal barrier function
would then be disrupted, and serum glycoproteins such as
amyloid P and immunoglobulins may be deposited resulting
in the formation of drusen.
One can postulate that in both AMD and DDD, the
inflammatory response to the ‘overactive’ complement path-
way leads to local tissue damage in susceptible areas such as
the retina and the glomerulus. There are distinct anatomical
similarities between the filtration complex of the glomerulus
and the retinal pigment epithelium–Bruch’s membrane-
choriocapillaris complex (Figure 3). The glomerular podo-
cytes, or foot processes, that wrap around the glomerular
capillaries can be compared with the retinal pigment
epithelial cells. They are separated by the GBM (which could
equate to Bruch’s membrane in the eye) from the fenestrated
capillary endothelial cells of the glomerulus and the
choriocapillaris, respectively. Both the GBM and Bruch’s
membrane are selectively and directionally permeable and
have a high heparan sulfate content.4 It is, therefore, not
surprising that these two areas could, in the appropriate
circumstances, respond in a similar fashion to appropriate
physiological or pathological insults. This speculation is
supported strongly by our findings, which show conclusively
that drusen in DDD and AMD have similar oligosaccharide
distributions and suggest that drusen may be a common end
result of differing ocular and systemic pathologies.
MATERIALS AND METHODS
Three renal specimens with biopsy-proven DDD and seven eyes
were used in this study. All tissue had been fixed in formalin
and embedded in paraffin wax. The DDD renal biopsies were
provided by the Department of Histopathology, Manchester Royal
Infirmary. Prior consent for research purposes was obtained. The
ages of the patients at the time of biopsy were 34, 21, and 19 years.
Two patients had proteinuria with hypertension and the third had
presented to the renal physicians with a nephritic syndrome. The
diagnosis of DDD had been confirmed in all cases by electron
microscopy.
Of the ocular specimens, the diagnosis in six cases was AMD and
the seventh eye was from a patient (patient A) who had died from
chronic renal failure. She had presented initially with a nephrotic
syndrome and partial lipodystrophy with hypocomplementemia; she
progressed to end-stage renal failure. Subsequently, she underwent
full ophthalmological examination and was found to have the
characteristic retinal lesions associated with DDD. The clinical renal
diagnosis was DDD, although native renal tissue was never obtained.
Three of the AMD eyes were obtained from the pathology archives
of the Manchester Royal Eye Hospital; these had been enucleated
surgically. The three other AMD specimens were donated by
Professor M Boulton (University of Texas). Consent had been given
for removal of the autopsy eyes for research purposes. The ages of
the three patients with AMD at enucleation were 69, 80, and 81
years, whereas the ages of the other three patients with AMD were
not available. The patient with presumed DDD was 38 years old at
a b
pigment
epithelium
Retinal 
Bruch’s
membrane
Pericyte
Mesangial cellVisceral epithelialcell
Endothelial
cell
Glomerular basement
membrane
Choroid
Retina
CHOROID – RETINA
GLOMERULUS
Choriocapillary endothelium
Figure 3 | Schematic diagram showing the comparison between the retinal pigment epithelium–Bruch’s membrane complex and
the glomerulus.
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the time of death, and eye tissue from this patient was obtained at
autopsy with consent from her family. The presence, location, and
size of drusen were determined histologically on sections stained
with hematoxylin and eosin, and periodic acid-Schiff. Kidney
material from patient A was unsuitable for any meaningful lectin
study as the histological appearance was of end-stage chronic renal
disease, with severe sclerosis of the remaining glomeruli.
The method used for determining the lectin histochemistry
incorporated a panel of 19 biotinylated lectins known to bind
saccharides present in mammals (see Table 3 and D’souza et al. for
the lectin-binding specificities) with an avidin peroxidase–DAB-
cobalt revealing system as described earlier, with and without
neuraminidase pre-treatment. Normal kidney and ocular tissue was
used as a positive control. Confirmation that the lectins were
binding through their binding sites was obtained by incubating the
lectin in the presence of 0.2 M of the appropriate competing sugar,
whereas reduction or abolition of staining by sialic acid-binding
lectins following neuraminidase predigestion was taken as con-
firmation of lectin specificity for sialyl residues. Ocular tissue
was used as a negative control. The lectin was replaced with 0.05 M
TBS, pH 7.6 containing 1 mM calcium chloride with each
experimental run.
A semi-quantitative ranking system was used to grade the
staining pattern, in which 0¼ no staining, 1¼weak staining,
2¼moderate staining, 3¼moderately strong staining, and
4¼ intense staining. The intensity of staining of each case was
recorded and the results then averaged for each pathological group.
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Table 3 | Biotinylated lectins used as probes and their major
sugar specificities
Lectin Source Major specificity
Mannose
Con-A Canavalia
ensiformis
aD-man, a-D-Glc, terminal or a1,2
N-linked sequences, high mannose,
intermediate, and small complex
structures.
PSA Pisum sativum a-D-man in non-bisected bi/tri
antennary complex N-glycan.
LCA Lens culinaris a-D-man, similar to but not identical to
PSA
e-PHA Phaseolus vulgaris
(erythroagglutinin)
Bisected bi/tri-antennate complex
N-glycan
l-PHA Phaseolus vulgaris
(leukoagglutinin)
Tri/tetra-antennate non-bisected
complex N-glycan
N-acetyl galactosamine
SBA Glycine max Terminal GalNAca1-
DBA Dolichos biflorus GalNAca1,3(Fuc1,2)Galb1,4GlcNAc-
Galactose
AHA Arachis hypogaea Galb1,3GalNAca-4Galb1,4GlcNAca1
Jacalin Artocarpus
integrifolia (Jacalin)
Galb1,3GalNAc-, Gala1,6-
MPA Maclura pomifera Galb1,3GalNAca1-4GalNAca1-
BSA-
1B4
Bandeiraea
simplicifolia
Gala1,3Galb1,4GlcNAcb-
ECA Erythrina cristagalli Galb1,4GlcNAc-
CTA Erythrina
corallodendron
Galb1,4GlcNAc-(multiple)
N-acetyl glucosamine oligomers
WGA Triticum vulgaris (-4GlcNAc b1,4GlcNAcb1-)n,
(-Galb1,4GlcNAcb1-)n
DSA Datura stramonium -GlcNAcb1,4GlcNAc-
Fucose
UEA-1 Ulex europaeus Fuca1,2Galb1,4GlcNAc-
LTA Tetragonolobus
purpureas
a-L-fucosyl terminals
Sialic acid
SNA-1 Sambucus nigra Neu5Aca2,6Gal/GalNAc-
MAA Maackia amurensis Neu5Aca2,3Galb1
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